Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | DRD3 | P35462 | 13/20 | 0.38 |
| ▸ | DRD2 | P14416 | 9/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18819904 | 0.84 | CDK4 (0.41) | CDK4FLT3PDCD1CD274DRD3 | |
| SCHEMBL21414409 | 0.81 | PNMT (0.44) | CDK4PDCD1CD274LMNAPOLB | |
| SCHEMBL18819902 | 0.81 | PDCD1 (0.52) | CDK4FLT3PDCD1CD274 | |
| SCHEMBL21452319 | 0.79 | CDK4 (0.42) | CDK4PDCD1CD274LMNAPOLB | |
| SCHEMBL18820431 | 0.79 | CDK4 (0.42) | CDK4FLT3PDCD1CD274LMNA | |
| SCHEMBL18291660 | 0.79 | CDK4 (0.44) | CDK4PDCD1CD274 | |
| SCHEMBL20038575 | 0.78 | MAPT (0.39) | FLT3PDCD1CD274LMNAPOLB | |
| SCHEMBL21451837 | 0.77 | POLB (0.41) | CDK4PDCD1CD274LMNAPOLB | |
| SCHEMBL12693988 | 0.77 | CDK4 (0.43) | CDK4FLT3PDCD1CD274LMNA | |
| SCHEMBL18806194 | 0.76 | ADORA2A (0.37) | CDK4FLT3PDCD1CD274LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172214-B1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121323-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | CDK6, CDK4, CDK7 | CDK4 2/4885FLT3 825/4885PDCD1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.